Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by Desjardins Global Asset Management Inc.

Desjardins Global Asset Management Inc. lifted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 15.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,123 shares of the company’s stock after purchasing an additional 1,070 shares during the quarter. Desjardins Global Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $85,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Money Concepts Capital Corp acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter worth approximately $25,000. Quilter Plc acquired a new stake in Teva Pharmaceutical Industries during the 1st quarter worth approximately $3,103,125,000. Tower Research Capital LLC TRC lifted its position in Teva Pharmaceutical Industries by 1,729.5% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,787 shares of the company’s stock worth $39,000 after acquiring an additional 3,580 shares during the period. Blue Trust Inc. lifted its position in Teva Pharmaceutical Industries by 92.3% during the 4th quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock worth $46,000 after acquiring an additional 2,180 shares during the period. Finally, Signaturefd LLC lifted its position in Teva Pharmaceutical Industries by 90.8% during the 3rd quarter. Signaturefd LLC now owns 5,032 shares of the company’s stock worth $51,000 after acquiring an additional 2,394 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on TEVA. Piper Sandler raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $12.00 to $19.00 in a research report on Monday, February 12th. The Goldman Sachs Group increased their price objective on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research report on Monday, February 5th. Jefferies Financial Group raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and increased their target price for the stock from $10.00 to $14.00 in a research note on Tuesday, January 23rd. Barclays increased their target price on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Finally, StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $13.78.

Teva Pharmaceutical Industries Stock Up 0.6 %

NYSE TEVA opened at $12.86 on Friday. Teva Pharmaceutical Industries Limited has a 1-year low of $7.09 and a 1-year high of $14.47. The business has a 50 day moving average price of $13.50 and a 200 day moving average price of $11.25. The company has a quick ratio of 0.69, a current ratio of 1.02 and a debt-to-equity ratio of 2.23.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 31st. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.25. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. The firm had revenue of $4.46 billion during the quarter, compared to the consensus estimate of $3.97 billion. As a group, analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In related news, VP Eric Drape sold 173,261 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $13.05, for a total value of $2,261,056.05. Following the completion of the transaction, the vice president now directly owns 1 shares of the company’s stock, valued at approximately $13.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Teva Pharmaceutical Industries news, VP Eric Drape sold 173,261 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the sale, the vice president now owns 1 shares in the company, valued at approximately $13.05. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Amir Weiss sold 31,766 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $12.37, for a total value of $392,945.42. Following the sale, the chief accounting officer now owns 10,676 shares in the company, valued at approximately $132,062.12. The disclosure for this sale can be found here. Insiders sold 390,738 shares of company stock valued at $5,132,766 in the last ninety days. Corporate insiders own 0.62% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.